Chemicals
Compare Stocks
2 / 10Stock Comparison
ORGN vs BIOX
Revenue, margins, valuation, and 5-year total return — side by side.
Agricultural Inputs
ORGN vs BIOX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Chemicals | Agricultural Inputs |
| Market Cap | $211M | $30M |
| Revenue (TTM) | $25M | $318M |
| Net Income (TTM) | $-69M | $-53M |
| Gross Margin | 1.8% | 39.1% |
| Operating Margin | -321.3% | 0.2% |
| Total Debt | $10M | $277M |
| Cash & Equiv. | $56M | $33M |
ORGN vs BIOX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Sep 20 | May 26 | Return |
|---|---|---|---|
| Origin Materials, I… (ORGN) | 100 | 0.5 | -99.5% |
| Bioceres Crop Solut… (BIOX) | 100 | 8.8 | -91.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ORGN vs BIOX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
ORGN is the clearest fit if your priority is income & stability and growth exposure.
- beta 1.68
- Rev growth 8.6%, EPS growth -441.2%
- Lower volatility, beta 1.68, Low D/E 2.9%, current ratio 11.09x
BIOX carries the broadest edge in this set and is the clearest fit for long-term compounding.
- -95.1% 10Y total return vs ORGN's -99.5%
- -16.6% margin vs ORGN's -275.0%
- -88.5% vs ORGN's -92.8%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 8.6% revenue growth vs BIOX's -28.3% | |
| Quality / Margins | -16.6% margin vs ORGN's -275.0% | |
| Stability / Safety | Beta 1.68 vs BIOX's 1.94, lower leverage | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | -88.5% vs ORGN's -92.8% | |
| Efficiency (ROA) | -6.7% ROA vs ORGN's -19.7%, ROIC -0.5% vs -19.6% |
ORGN vs BIOX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
ORGN vs BIOX — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
BIOX leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
BIOX is the larger business by revenue, generating $318M annually — 12.7x ORGN's $25M. Profitability is closely matched — net margins range from -16.6% (BIOX) to -2.8% (ORGN). On growth, BIOX holds the edge at -16.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $25M | $318M |
| EBITDAEarnings before interest/tax | -$70M | $21M |
| Net IncomeAfter-tax profit | -$69M | -$53M |
| Free Cash FlowCash after capex | -$55M | $37M |
| Gross MarginGross profit ÷ Revenue | +1.8% | +39.1% |
| Operating MarginEBIT ÷ Revenue | -3.2% | +0.2% |
| Net MarginNet income ÷ Revenue | -2.8% | -16.6% |
| FCF MarginFCF ÷ Revenue | -2.2% | +11.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | -43.2% | -16.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +57.7% | -37.3% |
Valuation Metrics
BIOX leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $211M | $30M |
| Enterprise ValueMkt cap + debt − cash | $164M | $274M |
| Trailing P/EPrice ÷ TTM EPS | -2.45x | -0.58x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | 20.01x |
| Price / SalesMarket cap ÷ Revenue | 6.74x | 0.09x |
| Price / BookPrice ÷ Book value/share | 0.60x | 0.10x |
| Price / FCFMarket cap ÷ FCF | — | 0.85x |
Profitability & Efficiency
BIOX leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
BIOX delivers a -16.7% return on equity — every $100 of shareholder capital generates $-17 in annual profit, vs $-22 for ORGN. ORGN carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to BIOX's 0.94x. On the Piotroski fundamental quality scale (0–9), BIOX scores 3/9 vs ORGN's 2/9, reflecting mixed financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -21.9% | -16.7% |
| ROA (TTM)Return on assets | -19.7% | -6.7% |
| ROICReturn on invested capital | -19.6% | -0.5% |
| ROCEReturn on capital employed | -20.8% | -0.8% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 3 |
| Debt / EquityFinancial leverage | 0.03x | 0.94x |
| Net DebtTotal debt minus cash | -$47M | $244M |
| Cash & Equiv.Liquid assets | $56M | $33M |
| Total DebtShort + long-term debt | $10M | $277M |
| Interest CoverageEBIT ÷ Interest expense | -417.10x | -0.07x |
Total Returns (Dividends Reinvested)
BIOX leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in BIOX five years ago would be worth $317 today (with dividends reinvested), compared to $48 for ORGN. Over the past 12 months, BIOX leads with a -88.5% total return vs ORGN's -92.8%. The 3-year compound annual growth rate (CAGR) favors BIOX at -64.0% vs ORGN's -77.7% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -79.9% | -65.0% |
| 1-Year ReturnPast 12 months | -92.8% | -88.5% |
| 3-Year ReturnCumulative with dividends | -98.9% | -95.3% |
| 5-Year ReturnCumulative with dividends | -99.5% | -96.8% |
| 10-Year ReturnCumulative with dividends | -99.5% | -95.1% |
| CAGR (3Y)Annualised 3-year return | -77.7% | -64.0% |
Risk & Volatility
Evenly matched — ORGN and BIOX each lead in 1 of 2 comparable metrics.
Risk & Volatility
ORGN is the less volatile stock with a 1.68 beta — it tends to amplify market swings less than BIOX's 1.94 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. BIOX currently trades 9.1% from its 52-week high vs ORGN's 5.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.68x | 1.94x |
| 52-Week HighHighest price in past year | $28.49 | $5.18 |
| 52-Week LowLowest price in past year | $0.20 | $0.35 |
| % of 52W HighCurrent price vs 52-week peak | +5.0% | +9.1% |
| RSI (14)Momentum oscillator 0–100 | 30.7 | 44.6 |
| Avg Volume (50D)Average daily shares traded | 161K | 804K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | — |
| Price TargetConsensus 12-month target | $90.00 | — |
| # AnalystsCovering analysts | 6 | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +3.1% |
BIOX leads in 4 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics. 1 category is tied.
ORGN vs BIOX: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is ORGN or BIOX a better buy right now?
For growth investors, Origin Materials, Inc.
(ORGN) is the stronger pick with 8. 6% revenue growth year-over-year, versus -28. 3% for Bioceres Crop Solutions Corp. (BIOX). Analysts rate Origin Materials, Inc. (ORGN) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ORGN or BIOX?
Over the past 5 years, Bioceres Crop Solutions Corp.
(BIOX) delivered a total return of -96. 8%, compared to -99. 5% for Origin Materials, Inc. (ORGN). Over 10 years, the gap is even starker: BIOX returned -95. 1% versus ORGN's -99. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ORGN or BIOX?
By beta (market sensitivity over 5 years), Origin Materials, Inc.
(ORGN) is the lower-risk stock at 1. 68β versus Bioceres Crop Solutions Corp. 's 1. 94β — meaning BIOX is approximately 15% more volatile than ORGN relative to the S&P 500. On balance sheet safety, Origin Materials, Inc. (ORGN) carries a lower debt/equity ratio of 3% versus 94% for Bioceres Crop Solutions Corp. — giving it more financial flexibility in a downturn.
04Which is growing faster — ORGN or BIOX?
By revenue growth (latest reported year), Origin Materials, Inc.
(ORGN) is pulling ahead at 8. 6% versus -28. 3% for Bioceres Crop Solutions Corp. (BIOX). On earnings-per-share growth, the picture is similar: Origin Materials, Inc. grew EPS -441. 2% year-over-year, compared to -1704. 7% for Bioceres Crop Solutions Corp.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ORGN or BIOX?
Bioceres Crop Solutions Corp.
(BIOX) is the more profitable company, earning -15. 5% net margin versus -267. 6% for Origin Materials, Inc. — meaning it keeps -15. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BIOX leads at -1. 1% versus -271. 3% for ORGN. At the gross margin level — before operating expenses — BIOX leads at 39. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — ORGN or BIOX?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is ORGN or BIOX better for a retirement portfolio?
For long-horizon retirement investors, Origin Materials, Inc.
(ORGN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Bioceres Crop Solutions Corp. (BIOX) carries a higher beta of 1. 94 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ORGN: -99. 5%, BIOX: -95. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between ORGN and BIOX?
Both stocks operate in the Basic Materials sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.